GMHC Treatment Issues Table of Contents, September, 1998

Now Live: Breaking Research From AIDS 2008: Podcasts, Interviews, Videos & More >>

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Gay Men's Health Crisis

GMHC Treatment Issues
Table of Contents, September, 1998

What Price Efavirenz?
Community outraged over drug pricing
Indinavir Alert
Merck announced that twice-a-day indinavir dosing is suboptimal and should be discontinued
An Even Dozen
Efavirenz goes through the FDA process very quickly to become the 12th approved antiretroviral agent, but is there enough evidence to support protease-sparing regimens?
The Other NNRTIs Merit Consideration
Data on nevirapine and delavirdine show promise for these two oft overlooked agents
Nucleotide Analogs' Toxic Side Effects
To benefit from adefovir and cidofovir, one must proceed with caution
Neuropathy Treatment Hits a Roadblock
Nerve Growth Factor for HIV-neuropathy expanded-access program called off

This article was provided by Gay Men's Health Crisis. It is a part of the publication GMHC Treatment Issues.

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.